Healthcare
GSK plc(GLAXF)
Live Price
Offline$25.70
-2.06% today
1Y Change
+39.04%
Window
Jun 25, 2025 โ Jun 24, 2026
- Market Cap
- $76.99B
- Revenue Growth
- +4.1%
- EPS Growth
- +123.8%
- Dividend Yield
- 3.4%
Coverage: 251 bars ยท Jun 25, 2025 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
GSK plc (GLAXF) is a Healthcare stock with a market cap of $76.99B and listed on OTC. The stock last traded around $25.70 and up 39.0% across the available one-year price window (Jun 25, 2025 โ Jun 24, 2026). Baseline metrics include revenue growth of +4.1%, EPS growth of +123.8%, a dividend yield of 3.4%. What stands out right now is revenue +4.1%, EPS +123.8%, free cash flow +66.7% with operating margin 22.3% and ROIC 15.5%. The dividend matters to the case here, with a current yield around 3.4%. Valuation is more restrained than many high-expectation growth names at P/E 13.3 and price/sales 2.3. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines GLAXF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+4.1% vs +7.6% peer median
Operating Margin
Above sector median
+22.3% vs +19.4% peer median
P/E
Below sector median
13.3 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report landed above expectations
2026 was reported on Apr 29, 2026 with an EPS surprise of +7.9% and a revenue surprise of -0.1%.
The operating story is still moving forward
Revenue is running at +4.1% and EPS at +123.8%, with operating margin around 22.3%.
The next real check-in already has a date
The next earnings event is scheduled for Jul 28, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +3.4% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 29, 2026 | +7.9% | -3.9% | -6.7% | -9.2% |
2026 Feb 4, 2026 | +7.1% | +6.2% | +9.1% | -3.7% |
2025 Oct 29, 2025 | -22.2% | +7.2% | +7.9% | +7.5% |
Benchmark Edge
GLAXF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
GLAXF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
GLAXF Max Drawdown
-23.95%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for GLAXF and SPY.
Company Overview
GSK plc
Other OTC
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
- Leadership
- Luke Victor Miels
- IPO Date
- Jan 5, 2010
- Employees
- 68.6k
- Street Address
- 980 Great West Road
- Mailing
- Brentford, TW8 9GS
- Region
- Brentford, GB
- Reporting Currency
- USD
- Investor Line
- 44 20 8047 5000
- Last Updated
- Apr 29, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 13.3
- EV/EBITDA
- 6.4
- Price/Sales
- 2.3
- Price/Book
- 4.3
Growth
- Revenue
- +4.1%
- EPS
- +123.8%
- Free Cash Flow
- +66.7%
Profitability
- Gross Margin
- 72.7%
- Operating Margin
- 22.3%
- Net Margin
- 17.8%
- ROE
- 35.8%
- ROIC
- 15.5%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.79
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.